Virtual Library
Start Your Search
Xue Li
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-041 - Pemetrexed plus Platinum Chemotherapy with or Without ImmunoResponses of Bevacizumab plus Cisplatin for the Non-Squamous Non-Small-Cell Lung Cancer Patients with Malignant Pleural Effusionstherapy in Non-Squamous NSCLC: Descriptive Safety Analysis (ID 9883)
09:00 - 09:00 | Presenting Author(s): Xue Li
- Abstract
Background:
To explore the efficacy and safety of intrapleural bevacizumab plus cisplatin for malignant pleural effusions (MPEs) of non-squamous non-small-cell lung cancer (NSCLC) patients.
Method:
We retrospectively analyzed 14 patients with MPEs who received intrapleural bevacizumab (200mg) plus cisplatin (60mg) from May, 2015 to March, 2017. Treatment response was assessed according to RECIST 1.1
Result:
The patients included 6 (42.6%) men and 8 (57.1%) women, with a median age of 54 years (ranged, 41-71 years). Five (35.7%) patients had smoking history. Thirteen (92.9%) patients had an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2. Driver gene alterations were detected in 4 (28.6%) patients, among them, 3 epidermal growth factor receptor mutations and 1 anaplastic lymphoma kinase arrangement. Four (28.6%) patients received first-line intravenous chemotherapy, and 10 (71.4%) had second or later line chemotherapy. In the management of MPEs, 8 (57.1%) patients achieved partial response (PR), 2 (14.3%) patients showed stable disease (SD) and 4 (28.6%) patients experienced progressive disease (PD). No one was seen complete response (CR). The overall response rate (ORR) and disease control rate (DCR) was 57.1% and 71.4%, respectively. There were 7 (50.0%) cases treated with bevacizumab and cisplatin as initial intrapleural therapy, another 7 (50.0%) patients as subsequent treatment. There were 4 (57.1%) PR for group with bevacizumab plus cisplatin as initial treatment and 4 (57.1%) PR for group with bevacizumab plus cisplatin as subsequent treatment. No significant difference was observed in the two groups (P=1.00). In addition, the adverse events we seen were myelosuppression (7.1%), nausea and emesis (28.5%), mainly in grade 1-2. No thrombosis or bleeding occurred in this study.
Conclusion:
Combined intrapleural therapy with bevacizumab and cisplatin was found to be effective for the non-squamous NSCLC patients with MPEs, and the adverse events were well tolerable.
